 |
Prospector
Profile
07.1499
|
| |
| Xeno Transplants Corp. |
NAICS |
541710 |
| 1066 West Hastings Street, Suite 2610
Vancouver, British Columbia, Canada V6E 3X2 |
Description |
Biotechnology |
| (604) 684-4691 |
Employees |
0 |
| http://www.xeno-transplants.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.1280 |
| |
Assets |
(mil) |
0.6410 |
| |
Liability |
(mil) |
0.2550 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Davidson & Company LLP raised substantial doubt about the ability of Xeno Transplants Corp. to continue as a going concern after auditing its financial statements. The Company has not earned any revenues since inception and has had a history of negative cash flows from operating activities. In addition, the Company has an accumulated deficit of $279,256 as of June 30, 2007.
|
| |
|
Intellectual Property:
On May 16, 2006, the Company's American Xeno, Inc. (AXI) subsidiary signed an exclusive license agreement with Massachusetts General Hospital to have the exclusive right to commercially develop, manufacture, distribute and use products and processes with regard to xenotransplantation. The license includes 38 issued U.S. patents and 51 issued international patents, with multiple patent applications. On January 31, 2007, AXI also acquired a patent assignment from Infigen, Inc. consisting of 2 issued U.S. and 7 issued international patents and multiple patent applications relating to producing pigs by cloning, including the methods used in producing the Company’s genetically engineered pigs. [SEC Filing 10-KSB 09-27-07]
|
| |
|
Description:
Xeno is a bio-technology research and development company that holds an exclusive commercial license from Massachusetts General Hospital derived from over 15 years of development in the field of xenotransplantation by Novartis Pharmaceuticals and its associated research entities.
|
| |
|
Officers:
Michael Perry (Chair, Pres. & CEO); Wayne Smith (CFO, Sec., Treas. & Dir.); David Sachs (Dir.); Milton Datsopoulos (Dir.); James Beckner (Dir.)
|
| |
|
Auditor:
Davidson & Company LLP
|
| |
|
Securities:
Common Stock-Symbol XENO.OB; OTC BB;
40,295,820 common shares outstanding as of September 17, 2007.
|
| |
| |
| |
| return to main page |
|
|
